Compare Ginkgo Bioworks Holdings Inc (DNA) vs Riot Platforms Inc (RIOT) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.

The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.

RIOT stock trades at $16.84, down 9.17% in the past 24 hours amid bearish technical signals. The company shows concerning fundamentals with a net income margin of -196.28% and negative cash flow from operations of -$573 million in 2025. However, analyst sentiment remains overwhelmingly positive with 18 buy ratings and a consensus price target of $31.64, representing 88% upside potential. Recent strategic shifts toward AI data center operations with $9.8 billion in contracted lease revenue through 2048 provide long-term growth catalysts.

The outlook remains polarized between strong analyst optimism and challenging financial performance. Investment opportunity exists in RIOT's strategic pivot to AI infrastructure with secured long-term revenue streams, but substantial execution risks persist given current profitability challenges and negative cash flow generation. Stock investors face volatility from both Bitcoin price sensitivity and the company's transition to new business models.